Loading...

Michael P Dube, MD

Title(s)Professor of Medicine (Clinical Scholar)
Phone+1 323 409 8288
vCardDownload vCard
    Other Positions
    Title(s)Associate Medical Director of the Rand Schrader AIDs Clinic

    Title(s)Interim Chief, Infectious Disease


    Collapse Overview 
    Collapse Overview
    Dr. Dubé is an attending physician at the Los Angeles County-USC Medical Center in Los Angeles. He is the Associate Director of the 5P21 Rand Schrader Health and Research Center at LA County-USC Medical Center. Dr. Dubé is also a Professor of Medicine at USC's Keck School of Medicine.

    Dr. Dubé earned his medical degree from Boston University School of Medicine. He then went on to complete his internship, residency and fellowship at LAC+USC Medical Center, specializing in Infectious Diseases.

    Collapse Research 
    Collapse Research Activities and Funding
    Microbial Translocation and HIV-Related Endothelial Dysfunction
    NIH/NIAID R21AI091492Sep 16, 2010 - Aug 31, 2013
    Role: Principal Investigator
    Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    NIH/NHLBI R01HL072711Sep 30, 2002 - Jul 31, 2009
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Blumenthal J, Moore DJ, Jain S, Sun X, Ellorin E, Corado K, Hoenigl M, Dube M, Haubrich R, Morris SR. Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. AIDS Patient Care STDS. 2019 May; 33(5):220-226. PMID: 31067122.
      View in: PubMed
    2. Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, Dube MP, Daar ES, Morris SR, Moore DJ. Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. J Infect Dis. 2018 10 05; 218(10):1551-1559. PMID: 30295803.
      View in: PubMed
    3. Corado K, Jain S, Morris S, Dube MP, Daar ES, He F, Aldous JL, Sitapati A, Haubrich R, Milam J, Karris MY. Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594. AIDS Behav. 2018 Aug; 22(8):2698-2710. PMID: 29725790.
      View in: PubMed
    4. Kelesidis T, Moser CB, Johnston E, Stein JH, Dube MP, Yang OO, McComsey GA, Currier JS, Brown TT. Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr. 2018 07 01; 78(3):362-366. PMID: 29533303.
      View in: PubMed
    5. Hassan A, Blumenthal JS, Dube MP, Ellorin E, Corado K, Moore DJ, Morris SR. Effect of rectal douching/enema on rectal gonorrhoea and chlamydia among a cohort of men who have sex with men on HIV pre-exposure prophylaxis. Sex Transm Infect. 2018 11; 94(7):508-514. PMID: 29907624.
      View in: PubMed
    6. Khan S, Funk CA, Corado K, Morris S, Dube MP. Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis. 2017; 4(3):ofx149. PMID: 30591921.
      View in: PubMed
    7. Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, Currier JS, Dube MP, Falutz J, Grinspoon SK, Guaraldi G, Martinez E, McComsey GA, Sattler FR, Erlandson KM. Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 May 15; 64(10):1422-1429. PMID: 28329372.
      View in: PubMed
    8. Kelesidis T, Jackson N, McComsey GA, Wang X, Elashoff D, Dube MP, Brown TT, Yang OO, Stein JH, Currier JS. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS. 2016 11 13; 30(17):2625-2633. PMID: 27603288.
      View in: PubMed
    9. Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017; 22(2):113-126. PMID: 27661466.
      View in: PubMed
    10. Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA. Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis. 2016 Sep; 3(3):ofw174. PMID: 27704026.
      View in: PubMed
    11. Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis. 2016 09 01; 214(5):748-52. PMID: 27354367.
      View in: PubMed
    12. Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, Dube MP, Morris SR, Gianella S. Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):133-7. PMID: 26818740.
      View in: PubMed
    13. Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S. Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):e48-50. PMID: 26977746.
      View in: PubMed
    14. Gianella S, Ginocchio CC, Daar ES, Dube MP, Morris SR. Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy. BMC Infect Dis. 2016 Jan 25; 16:24. PMID: 26809559.
      View in: PubMed
    15. Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dube MP, Little SJ, Smith DM, Lisco A, Gianella S. Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS. 2016 Jan; 30(2):193-201. PMID: 26558730.
      View in: PubMed
    16. Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10; 29(14):1775-83. PMID: 26372383.
      View in: PubMed
    17. Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep. 2015 Aug 24; 5:13179. PMID: 26299251.
      View in: PubMed
    18. Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR. Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. PLoS One. 2015; 10(6):e0130410. PMID: 26061824.
      View in: PubMed
    19. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15; 61(4):651-60. PMID: 25904376.
      View in: PubMed
    20. Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014 Jul; 88(14):7818-27. PMID: 24789781.
      View in: PubMed
    21. Blumenthal J, Haubrich R, Jain S, Sun X, Dube M, Daar E, Milam J, Morris S. Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART. Int J STD AIDS. 2014 Sep; 25(10):734-41. PMID: 24452730.
      View in: PubMed
    22. Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM. Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis. 2014 Feb 01; 209(3):452-6. PMID: 23964106.
      View in: PubMed
    23. Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1293-9. PMID: 23944767.
      View in: PubMed
    24. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013 Nov; 57(10):1483-8. PMID: 23943825.
      View in: PubMed
    25. Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang F, Ginocchio CC, Haubrich RH, Morris SR. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis. 2013 Aug; 57(3):441-7. PMID: 23595831.
      View in: PubMed
    26. Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 2014 Apr; 14(2):160-70. PMID: 23588107.
      View in: PubMed
    27. Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010 Mar 27; 24(6):885-90. PMID: 19952712.
      View in: PubMed
    28. Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K, Powderly W, Grinspoon SK, Dube MP. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008 Aug 20; 22(13):1561-8. PMID: 18670214.
      View in: PubMed
    29. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 01; 43(5):645-53. PMID: 16886161.
      View in: PubMed
    30. Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, Wolfe ML, Dube MP, Tebas P, Reilly MP. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006 Mar; 3(3):e52. PMID: 16417409.
      View in: PubMed
    31. Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, Hammer S, Currier J. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 03; 18(18):2434-7. PMID: 15622323.
      View in: PubMed
    32. Heiser CR, Ernst JA, Barrett JT, French N, Schutz M, Dube MP. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care (Chic). 2004 Oct-Dec; 3(4):121-9. PMID: 15768732.
      View in: PubMed
    33. Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis. 2003 Apr 01; 36(Suppl 2):S79-83. PMID: 12652375.
      View in: PubMed
    34. Aberg JA, Williams PL, Liu T, Lederman HM, Hafner R, Torriani FJ, Lennox JL, Dube MP, MacGregor RR, Currier JS. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis. 2003 Apr 01; 187(7):1046-52. PMID: 12660918.
      View in: PubMed
    35. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Am J Physiol Endocrinol Metab. 2002 Dec; 283(6):E1214-22. PMID: 12388173.
      View in: PubMed
    36. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001 Oct 19; 15(15):2001-10. PMID: 11600829.
      View in: PubMed
    37. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, Azen S. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1999 Apr; 84(4):1268-76. PMID: 10199766.
      View in: PubMed
    38. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998 Jun; 10(6):41-4. PMID: 11365497.
      View in: PubMed
    39. Dib JC, Dube M, Kelly C, Rinaldi MG, Patterson JE. Evaluation of pulsed-field gel electrophoresis as a typing system for Candida rugosa: comparison of karyotype and restriction fragment length polymorphisms. J Clin Microbiol. 1996 Jun; 34(6):1494-6. PMID: 8735104.
      View in: PubMed
    40. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec 15; 121(12):905-11. PMID: 7978715.
      View in: PubMed
    41. Dube MP, Davis FB, Davis PJ, Schoenl M, Blas SD. Effects of hyperthyroidism and hypothyroidism on human red blood cell Ca2+-ATPase activity. J Clin Endocrinol Metab. 1986 Feb; 62(2):253-7. PMID: 2934403.
      View in: PubMed